Targeting MET in NSCLC: An Ever-Expanding Territory

MET protooncogene (MET) alterations are known driver oncogenes in NSCLC. Since the identification of MET as a potential therapeutic target, extensive clinical trials have been performed. As a result, MET-targeted therapies, including MET tyrosine kinase inhibitors, monoclonal antibodies, and MET ant...

Full description

Bibliographic Details
Main Authors:	Ying Han, MD, Yinghui Yu, MD, Da Miao, MD, Mo Zhou, MD, Jing Zhao, MD, Zhehua Shao, MD, PhD, Rui Jin, MD, Xiuning Le, MD, PhD, Wen Li, MD, Yang Xia, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2024-02-01
Series:	JTO Clinical and Research Reports
Subjects:	MET Tyrosine kinase inhibitor Monoclonal antibodies Antibody-drug conjugate Non–small cell lung cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S266636432300173X

Internet

http://www.sciencedirect.com/science/article/pii/S266636432300173X

Targeting MET in NSCLC: An Ever-Expanding Territory

Internet

Similar Items